XORTX Therapeutics Inc (XRTX) - Net Assets
Based on the latest financial reports, XORTX Therapeutics Inc (XRTX) has net assets worth CA$1.97 Million CAD (≈ $1.43 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$2.81 Million ≈ $2.03 Million USD) and total liabilities (CA$837.41K ≈ $605.77K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read XRTX total debt and obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$1.97 Million |
| % of Total Assets | 70.21% |
| Annual Growth Rate | 47.67% |
| 5-Year Change | 165.6% |
| 10-Year Change | N/A |
| Growth Volatility | 523.89 |
XORTX Therapeutics Inc - Net Assets Trend (2018–2024)
This chart illustrates how XORTX Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore XORTX Therapeutics Inc total assets for the complete picture of this company's asset base.
Annual Net Assets for XORTX Therapeutics Inc (2018–2024)
The table below shows the annual net assets of XORTX Therapeutics Inc from 2018 to 2024. For live valuation and market cap data, see XORTX Therapeutics Inc (XRTX) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$3.34 Million ≈ $2.41 Million |
-28.12% |
| 2023-12-31 | CA$4.64 Million ≈ $3.36 Million |
-33.45% |
| 2022-12-31 | CA$6.97 Million ≈ $5.05 Million |
-58.33% |
| 2021-12-31 | CA$16.74 Million ≈ $12.11 Million |
+1232.35% |
| 2020-12-31 | CA$1.26 Million ≈ $908.75K |
+693.35% |
| 2019-12-31 | CA$-211.72K ≈ $-153.16K |
-165.85% |
| 2018-12-31 | CA$321.54K ≈ $232.60K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to XORTX Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1503923100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$24.50 Million | 734.44% |
| Total Equity | CA$3.34 Million | 100.00% |
XORTX Therapeutics Inc Competitors by Market Cap
The table below lists competitors of XORTX Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TwentyFour Select Monthly Income Fund Ltd
LSE:SMIF
|
$3.55 Million |
|
Saferoads Holdings Ltd
AU:SRH
|
$3.56 Million |
|
Emergent Metals Corp
V:EMR
|
$3.56 Million |
|
CN Energy Group Inc
NASDAQ:CNEY
|
$3.56 Million |
|
BELLUSCURA PLC LS -01
F:9VQ
|
$3.55 Million |
|
XP Chemistries AB
ST:XPC
|
$3.54 Million |
|
STL Global Limited
NSE:SGL
|
$3.54 Million |
|
PROSPECT RIDGE RESOURCES
F:0ED
|
$3.53 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XORTX Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,642,026 to 3,336,537, a change of -1,305,489 (-28.1%).
- Net loss of 3,313,346 reduced equity.
- New share issuances of 3,500,542 increased equity.
- Other factors decreased equity by 1,492,685.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-3.31 Million | -99.3% |
| Share Issuances | CA$3.50 Million | +104.92% |
| Other Changes | CA$-1.49 Million | -44.74% |
| Total Change | CA$- | -28.12% |
Book Value vs Market Value Analysis
This analysis compares XORTX Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 62.84x to 3.93x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | CA$0.06 | CA$3.77 | x |
| 2019-12-31 | CA$-0.04 | CA$3.77 | x |
| 2020-12-31 | CA$0.18 | CA$3.77 | x |
| 2021-12-31 | CA$1.29 | CA$3.77 | x |
| 2022-12-31 | CA$4.18 | CA$3.77 | x |
| 2023-12-31 | CA$2.32 | CA$3.77 | x |
| 2024-12-31 | CA$0.96 | CA$3.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XORTX Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -99.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.23x
- Recent ROE (-99.30%) is above the historical average (-218.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -1174.33% | 0.00% | 0.00x | 3.93x | CA$-3.81 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-608.40K |
| 2020 | -102.26% | 0.00% | 0.00x | 1.82x | CA$-1.41 Million |
| 2021 | -9.87% | 0.00% | 0.00x | 1.32x | CA$-3.33 Million |
| 2022 | -100.20% | 0.00% | 0.00x | 1.77x | CA$-7.69 Million |
| 2023 | -46.49% | 0.00% | 0.00x | 1.18x | CA$-2.62 Million |
| 2024 | -99.30% | 0.00% | 0.00x | 1.23x | CA$-3.65 Million |
Industry Comparison
This section compares XORTX Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $24,209,535
- Average return on equity (ROE) among peers: -379.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XORTX Therapeutics Inc (XRTX) | CA$1.97 Million | -1174.33% | 0.42x | $3.55 Million |
| Appili Therapeutics Inc (APLI) | $-13.40 Million | 0.00% | 0.00x | $1.86 Million |
| Aptose Biosciences Inc (APS) | $7.33 Million | -189.11% | 0.18x | $4.36 Million |
| Arch Biopartners Inc (ARCH) | $1.06 Million | -79.15% | 0.19x | $20.88 Million |
| Biomind Labs Inc (BMND) | $-1.30 Million | 0.00% | 0.00x | $6.98 Million |
| Cybin Inc (CYBN) | $237.20 Million | -47.70% | 0.09x | $301.37 Million |
| Eupraxia Pharmaceuticals Inc (EPRX) | $1.18 Million | -3177.89% | 21.71x | $393.86 Million |
| Devonian Health Group Inc (GSD) | $14.25 Million | -32.28% | 0.35x | $20.01 Million |
| Helix BioPharma Corp. (HBP) | $-1.39 Million | 0.00% | 0.00x | $116.58 Million |
| Hemostemix Inc (HEM) | $-6.77 Million | 0.00% | 0.00x | $8.18 Million |
| Universal Ibogaine Inc (IBO) | $3.94 Million | -266.20% | 0.60x | $1.13 Million |
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the … Read more